STARMED

Rollout Plan

STARMED will begin rolling out its refreshed brand identity from January 2026. The update will appear first in high visibility touchpoints such as our website and social channels, campaign and corporate communications assets, brochures and training materials, and event materials. Product related printed materials and packaging will transition progressively throughout 2026, as inventory cycles and local requirements must be considered, and during this period the previous and refreshed identities may appear in parallel. This update does not change product naming, performance, or safety, and the latest logos and guidelines are available in the Partner’s Center page.

Not long ago, the idea of treating a tumor without surgery seemed radical. Yet over the decades, oncology has continually advanced toward less invasive, more targeted therapies. From the surgeon’s scalpel to focused beams of radiation, to systemic chemotherapies, and then to image-guided interventions. Each step made treatment a little less taxing on patients. In the last few decades, we saw the rise of a new paradigm: image-guided ablation.

Treating tumors through an electrode-based intervention instead of an open surgery. When we started STARMED, radiofrequency ablation (RFA) was just emerging as a way to treat tumors with heat via a needle electrode. This technology allowed doctors to destroy diseased tissue from the inside out, sparing patients from large incisions. It was a revolutionary improvement in patient experience: no big scars, minimal anesthesia, and faster recovery times. But the evolution of treatment doesn’t stop there. We believe we are now at the beginning of the next chapter for less-invasive treatment, and it will also be the next chapter for our company.

Embracing a Multi-Modality Future

As our technology portfolio expanded over the years, our brand remained tightly tied to just one energy modality. In truth, we are no longer “just an RFA company” and we haven’t been for some time. Our established identity, as it stands, cannot represent everything we do today, let alone what we plan to do in the future. This realization comes at a pivotal moment for us. As we prepare for our next stage of corporate growth, we have a one-time opportunity to broaden our identity and share our vision on a global stage.

That is why today I am proud to share that STARMED is unveiling a refreshed brand and design identity. To reflect who we are and the future we hope to build. Our mission remains the same, it’s still about enhancing the quality of life by advancing technology. Importantly, our products and services aren’t changing their names or functionality. Think of it this way: we’re adding more chapters to our story, not discarding the earlier ones.

The Opportunity Ahead

Why make this change? By broadening our scope to a multi-modality future, we are positioning ourselves in front of a much larger opportunity. Consider the market trends in healthcare: the global demand for energy-based tumor therapies is expanding rapidly, driven by rising cancer cases and a worldwide push for less invasive treatments.

What’s particularly exciting is that this growth is not limited to RFA alone. While RFA currently accounts for the largest share of ablation procedures other modalities are catching up fast. Microwave ablation (MWA) is the fastest-growing segment globally, thanks to its ability to rapidly create large ablation zone. Cryoablation is seeing renewed interest for certain indications because of its unique ability to preserve surrounding healthy structures and to reduce procedural pain by freezing the tumor. Emerging techniques like high-intensity focused ultrasound (HIFU), and even non-thermal approaches such as irreversible electroporation (IRE), are on the horizon for broader clinical use. In short, our field is evolving into a multi-technology landscape.

By evolving our company to embrace multiple energy-source treatments, we open ourselves to all of these growing segments, not just one. We estimate that the addressable market for our solutions expands several-fold when we look beyond RFA alone. That means we can help more patients, address a wider range of conditions, and yes, access greater revenue potential which in turn fuels even more innovation. In the end, more lives can be improved or saved through therapies that are targeted, effective, and far less invasive than traditional surgery.

Built on a Strong Foundation

We are fortunate to be making this bold expansion from a position of strength. Thanks to years of steady growth and prudent management, our company’s financial foundation is rock-solid. Our core RFA business has been consistently profitable, and it has effectively funded our research and development into new areas. We intend to keep it that way. This is very much in line with a philosophy we’ve held from day one: “We do not build products to make money; we make money to serve humanity better.” That guiding principle has served us well, allowing us to continually reinvest in cutting-edge innovation.

You can see the results of this approach in our track record. For example, our team’s relentless R&D efforts led to the development of the world’s first RFA electrode for thyroid nodule, as well as the world’s first (and so far only) multi-pronged “Octopus” RF electrode for treating challenging tumors. Achievements like these, which were once considered aggressive or long-shot ideas, have translated into real improvements in patient care and significant growth for our company. We will maintain our commitment to bold, long-term investments in technology that improves patients’ lives.

Looking Ahead

Our new brand marks a natural evolution in our strategic journey. This change is part of a well-considered plan to allocate our capital and resources where they can have the greatest impact. We are building on the strong foundation we already have and expanding it to reach new heights. What doesn’t change is our core purpose or our commitment to those we serve. We remain dedicated to improving patient outcomes and advancing medical technology, just as we always have.

We stand at the forefront of a remarkable movement in medicine. One that is expanding organ-preserving, less invasive therapies into areas that used to require major surgery. The idea that a patient’s lesion can be destroyed without an open operation was once almost science fiction; today it’s a reality, and tomorrow it will be the standard of care for more and more conditions. That is the future we’re working to build.

Under the STARMED banner, we will strive to make that future arrive even sooner. We will broaden the reach of therapies that save lives while sparing patients trauma and downtime. We will continue to innovate responsibly, ambitiously, and with the patient at the center of every decision. And we will do it side by side with all of you: the doctors, nurses, technicians, researchers, distributors, and countless others who share our mission.

Thank you for your continued trust and partnership as we enter this new era. Together, we will drive the next chapter of innovation in less invasive treatment and beyond. I can’t wait to see what we will accomplish next.

About Us

STARMED unveils a refreshed brand identity